A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4 and R5 are defined herein, are useful as JAK kinase inhibitors. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of JAK kinase activity in a patient are disclosed.
公式I的化合物、对映体、二对映异构体、互变异构体或其药用可接受的盐,其中R1、R2、R3、R4和R5在此处定义,可用作JAK激酶
抑制剂。公开了包含公式I的化合物和药用可接受的载体、辅料或载体的药物组合物,以及治疗或减轻患者对JAK激酶活性抑制响应的疾病或病情的方法。